Structure
Signal peptide first, exactly one transmembrane segment per chain, zone order from extracellular to intracellular, no premature stop codons, no duplicated domain sequences.
Cell and gene therapy · construct validation
Find the flaw in a CAR-T construct before the bench does
CAR-T-check is a validation layer for chimeric antigen receptor constructs: it reads your design, applies 27 design rules — 15 of them literature-referenced — and points at the element that is wrong.
A misplaced signal peptide, a second transmembrane segment, a 2A element without its GSG spacer — mistakes that cost a cloning round and weeks of culture. Every element carries its source and its clinical standing, so a finding can be checked rather than believed.
The composer, plasmid map and 3D viewer are open without an account. Sequence analysis is in closed beta.
What gets checked
Topology
CD3ζ positioned C-terminally, hinge and spacer between scFv and membrane, multi-chain constructs split correctly at 2A elements, scFv carrying a flexible VL/VH linker.
Expression
Redundant leader sequences, GSG before a 2A element, sequence diversity between multiple 2A elements, secreted payloads carrying their own leader, transduction markers.
Provenance
Every element carries its source. Clinical standing where a variant is not an approved product, PubMed identifiers throughout, and patent search hints — flagged as hints, because freedom to operate is a question for a patent attorney, not for a database lookup.
In the tool
- Domain library66 entries with variants, sequences and citations
- Construct composerDrag-and-drop assembly with live rule checking and correction proposals
- Plasmid mapLength-true assembly into a real backbone, circular and linear, GenBank export
- 3D synapse viewerThe construct rendered at the tumour contact, violations marked in place
- Sequence searchBLAST against nr, literature lookup, AI-assisted safety assessment
What this is not
CAR-T-check is a research tool. It does not approve a construct, it does not replace a wet-lab validation, and nothing it reports is a regulatory statement or legal advice. Its patent information is a search hint, never a freedom-to-operate analysis — that is a patent attorney’s call. Where a domain variant has no clinical standing, the tool says so on the element itself rather than in a disclaimer at the bottom of a page.